Cannabis company Dancann Pharma's rights issue was subscribed to approximately 56,7 percent, including top underwriting commitments. This is stated in a press release.

The issue was subscribed to 31,5 percent with the support of subscription rights, to 6,4 percent without the support of subscription rights, and to 18,9 percent through the top underwriters.

The company will receive DKK 6.9 million before issue costs through the issue.

In addition, debt of DKK 3.35 million with a lender is converted into shares in the company.

Combined for both the issue and the debt conversion, the dilution effect for existing shareholders is 89.2 percent.